Cover Image
市場調查報告書

肥厚性疤痕治療藥的開發平台分析:臨床試驗&結果、專利、指定、聯盟、其他趨勢

Hypertrophic Scars Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

出版商 P&S Market Research Pvt. Ltd 商品編碼 600280
出版日期 內容資訊 英文 47 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
肥厚性疤痕治療藥的開發平台分析:臨床試驗&結果、專利、指定、聯盟、其他趨勢 Hypertrophic Scars Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments
出版日期: 2017年11月01日 內容資訊: 英文 47 Pages
簡介

本報告提供肥厚性疤痕治療藥的開發平台趨勢調查,各階段、分子類型、投藥途徑、企業的開發平台趨勢,藥物簡介,競爭環境,主要企業的基準,主要企業簡介等彙整。

第1章 調查背景

  • 調查目的
  • 市場定義
  • 調查範圍
  • 主要相關利益者

第2章 調查手法

  • 二次調查
  • 一次調查

第3章 摘要整理

第4章 開發平台的展望

  • 概要
  • 主要的成長推動因素
  • 主要的障礙
  • 開發平台分析
    • 各階段
    • 各分子類型
    • 各投藥途徑
    • 各企業

第5章 開發平台分析:各階段

  • 第二階段:藥物簡介
    • 前臨床研究
    • 前臨床研究結果
    • 臨床試驗
    • 臨床結果
    • 策略性開發
    • 指定
    • 津貼
    • 專利
    • 技術
  • 第一階段:藥物簡介
    • 前臨床研究
    • 前臨床研究結果
    • 策略性開發
    • 指定
    • 津貼
    • 專利
    • 技術
  • 開發中止的治療藥

第6章 臨床試驗分析

  • 臨床試驗:各地區
  • 臨床試驗:各檢測狀況

第7章 競爭環境

  • 主要企業的基準
  • SWOT分析

第8章 企業簡介

  • 產業概要
  • 提供產品與服務

第9章 附錄

目錄

Hypertrophic scars currently exhibits a growing pipeline with nine drug candidates, P&S Market Research

Hypertrophic scars therapeutics pipeline in 2017

Body cells known as myofibroblasts produce excessive collagen during healing process which can be deposited as a bump and later changes to a hypertrophic scar. The study analyzed that the hypertrophic scars therapeutics pipeline comprises approximately nine drug candidates in different stages of development.

Insights on pipeline segments

Majority of the pipeline drug candidates are being developed to be administered by the topical route. SCX-001 cream has demonstrated anti-scarring effects in two in-vivo Pre-clinical dermal models. SCX-001 cream's safety as a topical agent has also been confirmed in non-clinical Investigational New Drug (IND) in-vitro and in-vivo studies.

Specific targeted therapy expected to create opportunities for the pharmaceutical companies

The drug development process involves specific targets such as connective tissue growth factor inhibition which is the probable mechanism of action for the treatment of hypertrophic scars. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development.

Technological advancements enhancing the Pipeline Growth

Technological advancements have been strengthening the development of pipeline drugs for the treatment of hypertrophic scars. For instance, The RNA interference (RNAi) technology, was used in the development of OLX101 by OliX Pharmaceuticals, Inc.

Some of the players developing drugs for the treatment of hypertrophic scars include RXi Pharmaceuticals Corporation, Sirnaomics, Inc., ScarX Therapeutics, Inc., and Scarless Laboratories, Inc.

Hypertrophic Scars Therapeutics Pipeline Analysis

By Phase

By Molecule Type

By Route of Administration

By Company

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Definition
  • 1.3 Research Scope
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

  • 4.1 Overview
  • 4.2 Key Drivers
  • 4.3 Key Barriers
  • 4.4 Hypertrophic Scars Therapeutics Pipeline Analysis
    • 4.4.1 Pipeline Analysis by Phase
    • 4.4.2 Pipeline Analysis by Molecule Type
    • 4.4.3 Pipeline Analysis by Route of Administration
    • 4.4.4 Pipeline Analysis by Company

Chapter 5. Hypertrophic Scars Therapeutics Pipeline Analysis by Phase (2017)

  • 5.1 Phase II: Drug profiles
    • 5.1.1 Pre-Clinical Study
    • 5.1.2 Pre-Clinical Results
    • 5.1.3 Clinical Trials
    • 5.1.4 Clinical Results
    • 5.1.5 Strategic Development
    • 5.1.6 Designation
    • 5.1.7 Grants
    • 5.1.8 Patent
    • 5.1.9 Technology
  • 5.2 Phase I: Drug profiles
    • 5.2.1 Pre-Clinical Study
    • 5.2.2 Pre-Clinical Results
    • 5.2.3 Clinical Trials
    • 5.2.4 Clinical Results
    • 5.2.5 Strategic Development
    • 5.2.6 Designation
    • 5.2.7 Grants
    • 5.2.8 Patent
    • 5.2.9 Technology
  • 5.3 Pre-Clinical: Drug profiles
    • 5.3.1 Pre-Clinical Study
    • 5.3.2 Pre-Clinical Results
    • 5.3.3 Strategic Development
    • 5.3.4 Designation
    • 5.3.5 Grants
    • 5.3.6 Patent
    • 5.3.7 Technology
  • 5.4 Discontinued Drugs

Chapter 6. Clinical Trials Analysis

  • 6.1 Clinical Trials by Region for Hypertrophic Scars Therapeutics Pipeline
  • 6.2 Clinical Trials by Trial Status for Hypertrophic Scars Therapeutics Pipeline

Chapter 7. Competitive Landscape

  • 7.1 Key Players Benchmarking for Hypertrophic Scars Therapeutics Pipeline
  • 7.2 SWOT Analysis Hypertrophic Scars Therapeutics Pipeline
    • 7.2.1 Strengths
    • 7.2.2 Weaknesses
    • 7.2.3 Opportunities
    • 7.2.4 Threats

Chapter 8. Company Profiles

  • 8.1 Business Overview
  • 8.2 Product and Service Offerings

Chapter 9. Appendix

  • 9.1 Abbreviations
  • 9.2 Related Reports

LIST OF TABLES

  • PIPELINE ANALYSIS OF HYPERTROPHIC SCARS THERAPEUTICS, BY COMPANY (2017)
  • DESCRIPTION OF PHASE II DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE II DRUG CANDIDATES
  • DESCRIPTION OF PHASE I DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE I DRUG CANDIDATES
  • DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES
  • LIST OF DISCONTINUED DRUG CANDIDATES
  • COMPANIES - AT A GLANCE

LIST OF FIGURES

  • RESEARCH METHODOLOGY
  • SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
  • BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE
  • HYPERTROPHIC SCARS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
  • HYPERTROPHIC SCARS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
  • HYPERTROPHIC SCARS THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
  • BREAKDOWN OF CLINICAL TRIALS, BY REGION
  • BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
  • KEY PLAYERS BENCHMARKING
  • SWOT ANALYSIS
Back to Top